Haemolytic transfusion reactions – how many are preventable? : 1
Effect of storage age of transfused blood on 48 hour Hb increment and recovery of 2,3 DPG in haematology patients : 2
Transfusion transmitted malaria – a slip through the net : 3
Understanding SHOT data : Encouraging active participation and putting the findings into context
Towards improving blood transfusion practice : 5
The status of the remaining ATM allele affects the response to DNA damage in 11q deleted CLL tumours : 6
Functional analysis of TEL-AML1 fusion protein in haematopoietic progenitor cells in vivo and in vitro : 7
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant Bcr-Abl positive chronic myeloid leukemia (CML) : 8
Development of a semi-quantitative method for obtaining chimerism data from tissue and archived material : 9
A UKHCDO national study of the molecular pathogenesis of type 1 von Willebrand disease (VWD) : 10
Structure of the leukaemia-associated Shwachman-Bodian-Diamond syndrome protein reveals a novel fold frequently targeted by disease mutations : 11
Real-time PCR measurement of microarray gene signatures for lymphoma diagnosis and monitoring : 12
Identification of E2A-HLF candidate target genes and their contribution to leukaemogenesis : 13
GCS-100, a Galectin 3 antagonist, is a novel caspase-9 apoptosis activating agent for the treatment of indolent B-cell malignancies : 14
Go6976 is a novel and potent inhibitor of JAK2 and JAK3 tyrosine kinases both in vitro and in cellular assays : 15
Lymphocytes, but not CD34+ or CD33+ myeloid cells, of MDS patients have a hypermethylated CDKN2B promoter : 16
Regulation of Hox genes by IL-3 in 32D and BaF/3 cells : 17
Analysis of erythropoietin receptor structure and signalling in non small cell lung carcinoma : 18
Disruption of membrane cholesterol inhibits pgp-mediated drug-efflux in AML cells : 19
Novel factor VIII mutations in the Scottish population : 20
A critical role of gene-modified MHC class I-restricted helper T cells in long-term tumour protection : 21
The novel proteasome inhibitor BzLLL-COCHO is a specific inhibitor of proteasome activity : 22
Human fetal haematopoietic stem cells show different telomere length dynamics from agematched post natal stem cells in a longitudinal study : 23
Haematopoietic colony formation is altered at times of infective exacerbation in pulmonary disease : 24
Selective reduction of plasmacytoid DCs in peripheral blood from ITP patients : 25
CD34 and VEGF-R2 mRNA expression is reduced but ve-cadherin and CD14 mRNA expression is increased in patients after elective aortic aneurysm repair : 26
CD34 and ve-cadherin mRNA expression is reduced in patients undergoing coronary angiography : 27
Elucidating the role of MLL in adult murine haematopoiesis : 28
Role of low-density lipoprotein receptor-related protein (LRP) in patients with elevated FVIII : C and venous thromboembolism
Anti-hypertension drug perindopril reduced levels of von Willebrand factor and d-dimers : 30
Loss of terminal fucose residue expression associated with Bombay phenotype influences plasma von Willebrand factor and factor VIII antigen levels : 31
A randomised control trial of patient self-management of oral anticoagulation compared with patient self-testing : 32
A thromboelastograph study on the effects of tissue-type plasminogen activator (t-PA), urokinase-type plasminogen activator (u-PA) and thrombin activatable fibrinolysis inhibitor (TAFI) on whole blood fibrinolysis : 33
Bleeding complications of oral anticoagulant therapy in a single centre : 34
High D-dimer levels at presentation with DVT are associated with poor clinical outcomes : 35
Treatment of HIV associated thrombotic thrombocytopenic purpura – importance of prompt diagnosis : 36
An evaluation of four methods of external quality assurance (EQA) for patient self-management of oral anticoagulation : 37
Does human semen contain a functional haemostatic system? A possible role for tissue factor pathway inhibitor in fertility through semen liquefaction : 38
The effects of isometric and treadmill exercise on platelet and endothelial function in patients with intermittent claudication : 39
The clinical utility of D-dimer testing in the diagnosis of deep venous thrombosis of patients with a low pretest probability : 40
Pseudo von Willebrand disease : 2B or not 2B? Cryoprecipitate induced platelet aggregation solves Hamlet's dilemma
Is there a true difference in recurrence rate of deep venous thrombosis between men and women? : 42
Interim results of the multi-centre survey of the management of antenatal venous thromboembolism in the UK and Ireland ′03–′05 – http://www.ukivtepsurvey.co.uk : 43
A comparison between venometry and D-dimer in screening for deep vein thrombosis : 44
Uptake of thromboprophylaxis in medical patients : 45
Monocytes and plasma tissue factor levels in normal individuals and patients with deep venous thrombosis of the lower limbs : Potential diagnostic tools?
Harris syndrome : A geographic perspective
Analysis of pregnancy complications in 25 women with factor XI deficiency : 48
von Willebrand factor in patients with aortic stenosis : 49
Venous thromboembolic risk profile in patients with confirmed VTE : Findings from a prospective outpatient treatment registry (VERITY)
The sensitive detection of antibodies to von Willebrand factor cleaving protease (ADAMTS-13) : 51
Clinical use of protamine for the emergency reversal of anticoagulation with low molecular weight heparin (LMWH) : 52
Improved computer assisted warfarin dosing : Modifications to the Hillingdon algorithm
Comparison of Coaguchek S INRs with hospital laboratory citrated plasma INRs. What is the truth? : 54
The impact of ABO, secretor and Lewis blood group genotypes on the occurence of atherothrombotic stroke : 55
The effect of corn trypsin inhibitor on whole blood thromboelastographic and thrombus generation parameters : 56
Soluble CD40L in peripheral artery disease : Relationship with disease severity, platelet markers and the effects of angioplasty
Herbal medicine usage in patients taking oral anticoagulants : 58
Tissue factor synthesis and expression by human proximal tubular cells : The source of increased urinary tissue factor secretion in disease?
Evaluation of dHPLC in the analysis of factor VII deficiency : 60
Quality control (QC) of point of care testing (POCT) prothrombin time monitors – the way forward : 61
Recombinant activated factor VII (rVIIa) : Predicting response in intractable bleeding
The use of recombinant factor VIIa in the management of major haemorrhage : Experience within the northern region of the UK
Post-partum haemorrhage in von Willebrand's disease : 64
Reproducibility of the endogenous thrombin potential by the calibrated automated thrombogram assay : 65
A multicentre calibration study of WHO International Reference Preparations for thromboplastin, rabbit (RBT/90) and human (rTF/95) : 66
Apoptotic resistance in childhood acute lymphoblastic leukaemia may involve upregulation of the phosphatidylinositol 3-kinase pathway : 67
PAD (PS-341/bortezomib, adriamycin and dexamethasone) as front-line therapy for untreated patients with multiple myeloma : 68
Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant Bcr-Abl positive lymphoid malignancies : 69
The role of second autografts in the long term management of myeloma : Disease characteristics at relapse are predictive of response and can guide therapeutic decisions
Immunoregulatory properties of B-CLL cells : 71
Does BAX UTR polymorphism impact on overall survival in multiple myeloma patients? : 72
Activity of alemtuzumab in relapsed/refractory in Waldenstrom's macroglobulinaemia (WM) : Effect of CD52 expression on response assessment and disease monitoring
UK – Nordic revised evidence-based guidelines for management of multiple myeloma (MM) : 74
Efficacy of thalidomide monotherapy in relapsed or refractory patients with multiple myeloma : A systematic review of the 42 clinical trials and 1629 patients
There is an incomplete relationship between the 3 adverse prognostic factors – IGVH mutation status, ATM mutations and Zap 70 expression in CLL : 76
Soft tissue plasmacytomas are characterised by a ‘myeloma-like’ immunophenotype and genotype and low level bone marrow involvement : 77
Rarity of IgH translocations in Waldenstrom's Macroglobulinaemia (WM) : 78
CD38 expression in B-CLL is not fixed and may change due to contact with activating stimuli found within the leukaemic microenvironment : 79
Definition and zebrafish modelling of the 11q23 critical region of deletion in CLL : 80
Screening for monoclonal gammopathy : Improved sensitivity using serum free light chain assays
Expansion of CMV-specific CD8+ T cells in patients with B-cell chronic lymphocytic leukemia (B-CLL) : 82
Central nervous system chemoprophylaxis in non-Hodgkin's lymphoma : A questionnaire-based survey evaluating current practice in the United Kingdom
Pre-stimulation of T cells from patients with myeloma improves proliferation in response to lysate pulsed autologous DC : 84
IgH sequence analysis in Waldenstrom's macroglobulinaemia (WM) and IgM MGUS : 85
A phase I/II trial of bortezomib and low dose intravenous melphalan (BM) for relapsed multiple myeloma : 86
Optimising the use of arsenic trioxide in ‘high risk’ acute promyelocytic leukaemia (APL) : The UK experience
High frequency of aberrant megakaryocyte antigenexpression on myelodysplastic erythroid cells : Normalization by inhibition of protein kinase C
A novel approach to MRD monitoring in AML, real-time quantification of leukaemia associated antigens (WT1, PRAME and G250) : 89
Gene expression profiling can identify novel MRD markers for AML : 90
Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient outcome : 91
FLT3 gene mutations in AML : 92
Acquired uniparental disomy for chromosome 13 is associated with FLT3-itd mutations in AML : 93
A specific pattern of histone deacetylase (HDAC) expression can be identified in acute myeloid leukaemia : Relevance for targeted therapy with histone deacetylase inhibitors
Dose reduction in new chemotherapy regimens – effect of co-incubation of gemtuzumab ozogamicin with low dose Ara-C and etoposide on acute myeloid leukaemia blasts in vitro : 95
The endoplasmic reticulum plays a key role in regulating sensitivity to apoptosis in Bcr-Abl expressing cells : 96
An evaluation of quality of life (QOL) in long term remission patients with adult acute myeloid leukaemia (AML) : 97
A novel Bcr-Abl mediated pro-survival pathway : Reduction of releasable calcium levels in the endoplasmic reticulum inhibits calcium dependent apoptotic signaling
A Cre/Lox system to evaluate the reversibility of leukaemia in a murine model : 99
Identification of target genes of the oncogenic transcription factors MLL-ENL and MLL-AF9 in myeloid progenitor cells : 100
Establishment of an in vitro model to identify the molecular mechanism of haematopoietic progenitor cell immortalisation by MLL-ENL : 101
Prevalence and management of transfusional iron overload following curative treatment for acute myeloid leukaemia : 102
Audit of compliance with NICE guidance on the use of imatinib for chronic myeloid leukaemia (CML) within the Yorkshire region : 103
FLT3 internal tandem duplication as a marker for minimal residual disease in acute myeloid leukaemia : 104
Serial but not single BCR-ABL transcript rises are predictive of ABL kinase mutations in chronic myeloid leukaemia patients treated by imatinib : 105
Development of a quantitative real-time PCR method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia : 106
Mobilisation of peripheral blood stem cells with G-CSF alone in patients with multiple myeloma : A single centre experience
Impact of in vivo T cell depletion on outcome following reduced intensity transplantation with matched related donors for Hodgkin lymphoma : comparison between two prospective studies
Lymphocytes treated by extracorporeal photopheresis can down-regulate cytokine production in untreated monocytes : 109
Retrospective review of patients with high risk of HBV disease undergoing reduced intensity conditioned (RIC) allogeneic BMT : 110
High dose melphalan or intermediate dose melphalan (70 mg/m2) supported by PBSC results in comparable response rates in elderly patients with myeloma : 111
Allogeneic stem cell transplantation with T cell depletion for acute myeloid leukaemia : 112
Reduced intensity conditioning transplants in patients with AML and poor risk MDS : A single centre experience, Manchester Royal Infirmary
Optimal timing of autologous peripheral blood stem cell harvest following priming with cyclophosphamide and G-CSF : Significant improvement in progenitor cell yield harvesting on day 9–10 compared with day 7–8
Incidence and clinical significance of human herpesvirus 6 and 7 viraemia in allogeneic stem cell transplant recipients : 115
Imatinib followed by reduced intensity allogeneic stem cell transplantation for eradication of minimal residual disease in chronic phase chronic myeloid leukaemia patients : 116
High-dose therapy for mantle cell lymphoma – the Nottingham experience : 117
Immune reconstitution following non-myeloablative transplantation using in vivo T cell depletion with alemtuzumab is similar to T cell replete myeloablative allogeneic stem cell transplantation : 118
TEL-AML1 fusion in childhood acute lymphoblastic leukaemia (ALL) : Demographics, clinical features, cytogenetic characteristics and prognosis
Functional p-glycoprotein and internal tandem duplications of FLT3 are characteristic of discrete populations of elderly AML patients : 120
Go6976, a novel and potent inhibitor of JAK2 and JAK3, reduces constitutive STAT activity and induces apoptosis in myeloid leukaemia and anaplastic lymphoma cells : 121
A genome wide array based single nucleotide polymorphism (SNP) analysis shows frequent uniparental disomy (UPD) due to somatic recombination in acute myeloid leukaemia (AML) : 122
Neural differentiation of human CD133 + CD34 + foetal liver stem cells in serum-free culture : 123
Donor factors are significantly associated with primary non-engraftment in recipients of reduced intensity conditioned (RIC) transplants from unrelated donors : 124
Human Langerhans cells in transplantation : Recipient cells survive conditioning but donor cells predominate at day 100
Enhanced detection of human neutrophil antigen (HNA) specific antibodies using two screening techniques : 126
Response to ciclosporin in myelodysplastic syndrome : A study of 49 cases from India
Low-dose thalidomide and prednisolone in myelofibrosis – experience in the United Kingdom : 128
Rasburicase is effective in the prophylaxis of tumour lysis syndrome when used over a short duration in patients with haematological malignancy : 129
Role of adhesion molecules in regulating neutrophil mobilisation from the bone marrow : 130
An open-label, unit dose-finding study evaluating the safety and platelet response of a novel thrombopoietic protein (AMG531) in thrombocytopenic adult patients (Pts) with immune thrombocytopenic purpura (ITP) : 131
Playing the field in haematology : 132
The role of supplementary prescribing in haematology : 133
Child, parent and healthcare worker acceptability of the ReFacto Rapid Reconstitution™ (R2) device : 134
Nebulous nebulisers : 135
Present and future treatment options for children with severe congenital neutropenia (Kostmann's syndrome) : 136
Use of Rituximab in acute refractory thrombotic thrombocytopenic purpura : 137
Activated protein C (APC) bound to microparticle-associated endothelial protein C receptor (EPCR) occurs in vivo and has anticoagulant properties : 138
Reduced VWF : Ag levels in Bombay phenotype are explained by a conformation-related increased susceptibility to ADAMTS-13 proteolysis
Investigation of relationship of von Willebrand factor antigen clearance with ADAMTS-13 activity and Tyr1584Cys polymorphism in type 1 von Willebrand disease : 140
Seven novel candidate mutations in exon 27 and 28 of von Willebrand gene in patients with type 1, type 2 M and unclassified von Willebrand disease : 141
Altered clearance of apoptotic endothelial cells in the presence of antiphospholipid antibodies provides a dual mechanism for thrombosis in antiphospholipid syndrome : 142
Pulmonary hypertension as a complication of haemolysis : 143
Prevalence and causes of severe anaemia among children admitted to the acute care unit, Mulago Hospital : 144
A 4 year study of aplastic anaemia from India : Epidemiology and response to treatment
Use of intravenous anti-D immunoglobulin in refractory chronic idiopathic thrombocytopenic purpura : 146
Caspofungin and G-CSF as first line therapy of pulmonary invasive fungal infections in 34 neutropenic patients with haematologic malignancies : 147
Blood transfusion avoidance by correction of the anaemia of chronic disease with small doses of recombinant erythropoietin (Epoetin alpha and Darbepoetin) : 148
An effective quality control approach to thrombophilia polymorphism assays : 149
Audit of investigation and management of patients with vitamin B12 deficiency : 150
Rituximab treatment for adults with persistent severe idiopathic thrombocytopenic purpura following splenectomy : 151
Long term remission from SLE-associated haemolytic anaemia following rituximab : 152
Developments in digital imaging for UK.NEQAS(H) blood cell and bone marrow morphology scheme : 153
Audit of a triage process for general haematology referrals : 154
UK survey of antibiotic and antifungal treatment of febrile neutropenia : 155
Serum erythropoietin in health and disease : 156
Specialist care in the community : Establishing a remote access clinic for haematology patients
Human babesiosis : An unusual cause of haemolytic anaemia
Audit of the use of 50 : 50 nitrous oxide-oxygen mixture (Entonox (R)) for sedation during bone marrow aspiration and biopsy : 159
An audit of the investigation of vitamin B12 and folate deficiencies in the elderly : 160
Eosinophilic fasciitis : The association with an underlying haematological disorder
Does the adherence of universal precautions correlate with the prevalence of blood borne infections? : 162
Lymphocyte clustering/clumping in B lymphoproliferative disorders is a reversible temperature dependent phenomenon : 163
Increased circulating endothelial cells in acute congestive heart failure : Comparison with von Willebrand factor and soluble E selectin
Bivalirudin for anticoagulation during cardiopulmonary bypass monitored with ecarin clotting time : 165
Use of fixed dose prothrombin complex concentrate for the reversal of oral anticoagulant therapy : 166
Fluorogenic substrates for the monitoring of thrombin generation : 167
Is there a potential problem with the use of intravenous DDAVP in patients with von Willebrand's disease or mild haemophilia A who have borderline fibrinogen levels? : 168
Evaluation of two new automated D-dimer assays and assessment of their diagnostic performance for exclusion of deep vein thrombosis : 169
Treatment of chronic hepatitis C infection in patients with bleeding disorders : 170
The risk for DVT related to surgery within a large tertiary hospital : Data retrieved from the DVT clinic and compared to a national database (VERITY)
Audit of women delivered with heritable bleeding disorders west of Scotland, 2000–2004 : 172
Quantitation of thrombin activatable fibrinolysis inhibitor (TAFI) in human semen : 173
Self-management of oral anticoagulation : What happens outside trial conditions?
The expression of tissue factor increases as mouse embryonic stem cells undergo differentiation : 175
Can oral anticoagulation be managed using telemedicine and patient self-testing? A pilot study : 176
Haemoperitoneum associated with ovulation in women with autosomal recessive bleeding disorders : 177
Do we need pre-operative baseline coagulation screens as a routine investigation in all orthopaedic trauma patients? : 178
Atypical haemolytic-uraemic syndrome at onset of acute promyelocytic leukaemia : 179
Cost-effectiveness of computer-assisted anticoagulant dosage – preliminary report : 180
A simple protocol for dealing with sub-theurapeutic anti-coagulation in patients with mechanical heart valves : 181
Development of an assay for the determination of the quantity and activity of clot bound thrombin in a plasma system : 182
Cefotaxime-associated acquired von Willebrand disease : 183
Zeta associate protein tyrosine kinase (ZAP-70) could be a new biomarker in the pathogenesis or prognosis of B-cell acute lymphoblastic leukaemia (ALL) : 184
Characterisation of mature T-cell proliferations by immunophenotyping combined with TCR Vbeta repertoire analysis by flow cytometry : 185
Serum free light chain assays in solitary bone plasmacytoma : 186
Variable expression of the polycomb group protein BMI-1 in B cell chronic lymphocytic leukaemia : 187
Thalidomide, cyclophosphamide, oral idarubicin and dexamethasone (T-CID) for patients with relapsed or refractory multiple myeloma : 188
CTD as first line therapy for multiple myeloma. A single centre experience : 189
Ex vivo drug sensitivity testing by TRAC assay (Tumour Response to Anti-neoplastic Compounds assay) – a fourth-generation test based on the DiSC assay : 190
An audit of the potential value of Ciprofloxacin prophylaxis during neutropenia in patients receiving CHOP based chemotherapy for non-Hodgkin's lymphoma : 191
An evaluation of quality of life (QOL) in patients after treatment for multiple myeloma (MM) : 192
Audit of high grade B non Hodgkin's lymphoma (NHL) in the South West region 2001 – scope for improvement in meeting government targets : 193
A cluster of cases of angioimmunoblastic T-cell lymphoma in Grampian : 194
Audit of high grade B non Hodgkin's lymphoma (NHL) in the South West region 2001 – clinical data on 337 new cases : 195
Velcade therapy in plasma cell malignancy-experiences in Northern Ireland : 196
An overview of the clinical usage of the anti-CD20 monoclonal antibody rituximab at the regional haematology unit, Belfast City Hospital : 197
The role of bone marrow sections and biopsy in the confirmation of marrow involvement by multiple myeloma : 198
The outcome of post-transplant lymphoproliferative disease in four patients : 199
Unusual complication of chronic lymphocytic leukaemia : Two cases with symptomatic urinary bladder infiltration
Sensory cervical myelopathy with Lhermitte's sign after fludarabine and cyclophosphamide treatment for chronic lymphocytic leukaemia : 201
Development of UK – Nordic guidelines for diagnosis & management of multiple myeloma (MM) : 202
Hairy cell leukaemia : A district general hospital's experience
Myelodsplastic syndrome with monosomy 7 following successful treatment of hairy cell leukaemia with cladribine : 204
CDKN1A promoter methylation occurs in lymphocytes of MDS patients : 205
Creating a standardised approach for relapsed acute myeloid leukaemia : 206
Is NG2 reactivity a useful screening test for MLL rearrangments in acute leukaemia? : 207
Human stem cell factor [SCF]-antibody enhances cytarabine-induced apoptosis and necrosis in human CD34+CD7+ resistant AML cells : 208
T helper cell responses to myelodysplastic bone marrow cells reveal a failure of immune tolerance and heterogeneity of effector responses : 209
Cyclin D1 expression in acute leukaemia : 210
Eosinophilia and chronic leucocytosis mimicking a myeloproliferative disorder in a patient on clozapine treatment : 211
Delayed presentation of AML after orchidectomey for a testicular tumour : 212
Two cases of chloroma that presented with neurological signs without bone marrow involvement : Initially thought to be lymphoma
Study on the effects of protein tyrosine kinase, protein tyrosine phosphatase and protein kinase C on the apoptotic process of human cortex neurons and leukemia cells managed by arsenic trioxide : 214
Calculating the required transfusion volume in children : our current practice gives insufficient volumes
No major role for heterozygous FANCD1/BRCA2 IVS7 splice site mutations in sporadic childhood AML : 216
A metaPCR based screen of FANCE sequence variation in childhood AML : 217
The influence of patient gender and subtype on HLA-DPB1 allele associations with childhood Hodgkin lymphoma : 218
The relationship between the familial Hodgkin lymphoma-linked HLA class II haplotype, DQ6-DR2, and susceptibility to childhood Hodgkin lymphoma : 219
Clustering of childhood leukaemia in the UK : 220
The novel D239G mutation in the NADH binding lobe of cytochrome b5 reductase affects its specificity for substrate : 221
Implementation of the National Newborn Screening Programme for Sickle Cell Disease and Thalassaemia Major in the South East sector : 222
Heterogeneity of the epsilon-gamma-delta-beta thalassaemias : Characterisation of 3 novel English deletions
The relationship between cerebral blood flow velocity measured by transcranial Doppler (TCD) and turbulence on magnetic resonance angiography (MRA) in patients with sickle cell anaemia (SCA) with and without neurological symptoms : 224
Anti-CD20 monoclonal antibody (rituximab) to treat autoimmune haemolytic anaemia : Report of six cases
The prevalence and clinical spectrum of paroxysmal nocturnal haemoglobinuria in Northern Ireland : 226
Evaluation of intranasal diamorphine together with oral morphine for management of acute sickle pain in children : 227
Efficacy and side effects of deferiprone in children with iron overload : 228
The measurement of urinary hydroxyurea in sickle cell anaemia : 229
Towards improving awareness of good blood transfusion practice : 230
Epstein's syndrome : Successful renal transplant made possible with HLA matched platelets
A snapshot of the use of Beriplex P/N within a large tertiary hospital : 232
Increased compliance with recording of transfusion observations following introduction of Blood Product Transfusion Observation Chart : 233
Low level BCR-ABL transcript positivity in long term survivors of allogeneic stem cell transplantation for CML : 234
Effective strategies for achieving and maintaining therapeutic itraconazole concentrations in allogeneic stem cell transplant recipients : 235
Retrospective review of prophylaxis for toxoplasmosis following allogeneic bone marrow transplantation : 236
Trends towards increased acute GvHD and higher transplant-related mortality in non-caucasians undergoing standard sibling allogeneic stem cell transplantation : A single centre 5-year study
Therapy related acute myeloid leukaemia (t-AML) following high dose therapy and stem cell transplant for acute lymphoblastic leukaemia (ALL) : 238
RICE/ICE is an effective PBSC mobilising regime in patients with aggressive lymphoma : 239
Recipient derived HPA-1a antibodies associated with prolonged refractory thrombocytopenia following allogeneic stem cell transplantation from HPA-1a positive donors : 240
Patterns of engraftment of T-cells, granulocytes, B-cells, NK cells and dendritic cells (BDCA1 and BDCA4) following RIC Allo HSCT : 241
Patients undergoing second mobilisation following a failed peripheral blood stem cell harvest : factors affecting successful re-mobilisation
Prophylactic stimulated granulocytes transfusions in allogeneic stem cell transplantation : a transplant nurse specialist provided service
Liver function abnormalities following alemtuzumab (Campath-1H) : A previously unrecognised first dose effect
The novel, dual Src/Bcr-Abl kinase inhibitor, BMS-354825, does not overcome the intrinsic insensitivity of quiescent chronic myeloid leukaemia stem cells to imatinib : 245
Regulated expression of the Tel/PDGFR beta tyrosine kinase drives mouse embryonic stem cell differentiation in the presence of leukaemia inhibitory factor : 246
Bcr-Abl kinase expression increases proteasome activity : 247
Persistent chromosomal instability and cross-linker sensitivity in Fanconi anaemia derived leukaemia cell lines with bi-allelic FANCD1/BRCA2 mutations : 248
Sustained control of haemolysis and symptoms and reduced transfusion requirements over a period of 2 years in paroxysmal nocturnal haemoglobinuria (PNH) with eculizumab therapy : 249
A tool for predicting haemoglobin variants : An aid to DNA diagnostics
Pulmonary function abnormalities in adults with sickle cell disease – relationships between morphological abnormalities on high resolution CT, pulmonary function tests and haemolysis : 251
A pilot study to assess the efficacy and tolerability of pegylated interferon alfa-2b and ribavirin for the treatment of relapsed or refractory hepatitis C infection in beta-thalassaemia patients : 252
Survival and neurological complications in children with sickle cell disorders : data from an East London neonatal cohort